Introduction
============

Sleep-related disturbances and insomnia have been shown to be higher in chronic obstructive pulmonary disease (COPD) sufferers than in the general population, with between 50 and 70% of patients reporting difficulty in initiating or maintaining sleep, or poor sleep quality.^[@bib1],[@bib2]^ Disturbed sleep has been found to be associated with more severe disease, frequent exacerbations and increased mortality in COPD.^[@bib3]^ Sleep quality is a good predictor of quality of life in patients with stable COPD.^[@bib2],[@bib4]^

The underlying mechanism for poor sleep quality in COPD is under debate. Sleep may be disturbed by cough or dyspnoea.^[@bib3]^ In addition, nocturnal oxygen desaturation (NOD) in patients with COPD has been investigated as a cause of nocturnal arousals,^[@bib5]^ but may be less of a stimulant than hypercapnia.^[@bib6]^ NOD probably occurs due to a variety of mechanisms, including more pronounced alveolar hypoventilation, particularly during REM sleep,^[@bib7]^ over-reliance on respiratory musculature^[@bib8]^ and ventilation/perfusion mismatch.^[@bib5],[@bib7]^ Daytime hypoxaemia has been shown to be independently associated with impaired sleep efficiency.^[@bib9]^ However, NOD can occur in COPD patients with mild or absent daytime hypoxaemia.^[@bib10; @bib11; @bib12]^

The relationship between NOD and sleep quality is unclear.^[@bib13]^ Lewis *et al*.^[@bib14]^ found no significant difference in self-reported sleep quality between nocturnal desaturators and non-desaturators in 59 patients with resting saturations of \<95% recruited from an outpatient COPD clinic. Improvements in nocturnal hypoxaemia have been seen in patients taking salmeterol^[@bib15]^ and tiotropium,^[@bib16]^ without consequent improvement in polysomnography or subjective sleep quality. Recently Nunes *et al*.^[@bib17]^ showed that melatonin may have potential for improving sleep quality in COPD.

There has been little research into non-pharmacological methods to improve sleep quality in patients with COPD. In an uncontrolled observational study in the United States, Soler *et al*.^[@bib18]^ showed that pulmonary rehabilitation (PR) was associated with a statistically significant improvement in sleep quality although the improvement in Pittsburgh Sleep Quality Index (PSQI) score of 1.1 was well short of the minimal clinically important difference of 3.0.^[@bib19]^ The potential for PR, an important aspect in the management of COPD,^[@bib20]^ to improve sleep quality remains uncertain.

The hypothesis that PR may improve sleep quality is based on the observation that PR has been shown to improve quality of life and exercise capacity,^[@bib21]^ and anxiety and depression.^[@bib22]^ Anxiety and depression have been specifically associated with poor sleep.^[@bib23]^ The prevalences of anxiety and depression are higher in patients with COPD than in the general population.^[@bib24],[@bib25]^ A recent systematic review of the effects of exercise training on sleep quality in middle-aged to older adults with sleep problems found that participation in an exercise programme had moderately positive effects on sleep.^[@bib26]^

Our research aimed to determine whether PR improved sleep quality in patients with COPD.

Materials and Methods
=====================

Study design and setting
------------------------

We carried out an observational 'before and after' study of patients with COPD attending an 8-week community PR programme. We compared self-reported sleep quality before and after attendance at hospital or community-based PR using the PSQI.^[@bib27]^ A control group of patients with COPD was simultaneously recruited from a general practice in the same community to ensure that changes in sleep quality in the observation group after completion of PR could be compared to changes in the control group over a comparable period. Research ethical approval was obtained (NRES Committee London-Central reference 11/LO/1156).

Participants
------------

The study group under observation was recruited from five hospital and community sites in South East London. All patients referred to PR (community and hospital referrals) from November 2011 until June 2012 were invited to participate in the research at their initial assessment. Eligibility criteria for the study included a diagnosis of COPD confirmed by spirometry (forced expiratory volume in 1s (FEV~1~)/forced vital capacity ratio (FVC) \<0.7) according to GOLD criteria^[@bib28]^ and suitability for participation in PR. Consent to participate in the study was implied by completion of the first sleep questionnaire. Participants who attended PR at least once a week for 8 weeks were invited to complete a second questionnaire.

The control group was recruited from a general practice in the same area. Patients on the practice COPD register suitable for referral to PR (criteria identical to the observation group) were invited by letter to participate in the study, and supplied with a copy of the PSQI. Consent to participate in the study was implied by completion of the first questionnaire. A second questionnaire was sent \~8 weeks later. Reminder letters were sent to patients who did not return the second PSQI.

Instruments
-----------

Sleep quality was measured in the observation and control groups using the PSQI, a self-rated subjective questionnaire comprising 19 individual questions that generate seven 'component' scores (sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbances, use of sleeping medication and daytime dysfunction).^[@bib27]^ Each component score is marked from 0 to 3, with a maximum total score of 21 and a minimum score of 0. The sum of the component scores yields a global PSQI score. A global score \<5 indicates 'good' overall sleep quality, whereas a score ⩾5 indicates 'poor' sleep quality with a diagnostic sensitivity and specificity of 89.6% and 86.5%, respectively.^[@bib27]^ In comparison with other tools to measure sleep, the PSQI has undergone extensive psychometric evaluation.^[@bib29]^ It has been shown to have high test--retest reliability^[@bib30]^ and construct validity^[@bib31]^ and has a reported minimal clinically important difference of 3.^[@bib19]^

Respiratory specific quality of life was measured using the COPD assessment test (CAT),^[@bib32]^ exercise capacity was measured using the incremental shuttle walk test (ISWT),^[@bib33]^ and anxiety and depression were measured using the Hospital Anxiety and Depression Scale (HADS).^[@bib34]^

Data analysis
-------------

Sample size calculation was based on average PSQI scores in previous research with similar patients,^[@bib4],[@bib35]^ and a minimal clinically important difference of 3 between before and after measurements.^[@bib19]^ An expected correlation of *r*=0.8 between before and after PSQI measurements was used (compared to published values of 0.85) as the interval between before and after measurements in this study was slightly longer (PR course took place over 8 weeks).^[@bib27]^ Twenty-five patients with complete data were required in the intervention and control groups to give 90% power to detect a difference at the 5% significance level. To allow for drop-outs and losses to follow-up of 40%, at least 42 patients were approached in each group.

We analysed the data using SPSS v 20 (IBM, New York, NY, USA). The primary outcome measure was the change in individual PSQI scores in the observation group, before and after PR, compared with change in the control group. Secondary outcome measures were changes in HADS, CAT and exercise test scores in the observation group. We used the paired-samples Student *t*-test to compare means before and after, and the independent-samples Student *t*-test to compare differences between the two groups at baseline. Pearson's product moment co-efficient (*r*) was used to analyse association between changes in HADS, PSQI and CAT scores in the observation group.

Results
=======

Demographics
------------

Sixty-one eligible patients were recruited for the observation arm of the study, of whom 31 completed at least eight sessions of PR. Of these, 28 completed the first and second PSQI and were included in the final analysis. Recruited patients who completed PR or who were excluded or dropped out from the observation arm of the study are shown in [Figure 1](#fig1){ref-type="fig"}. The drop-out rate after the first assessment was 49%. Forty-two patients were invited to participate in the control group, of whom 24 returned the first and second PSQI.

Prevalence of poor sleep quality
--------------------------------

The prevalence of poor sleep quality (PSQI⩾5) in both the observation and control groups was 75%, with no statistically significant difference between them with respect to initial PSQI scores (*t*=−0.735, *P*=0.466). There was no difference between the baseline PSQI scores in the observation group and the 'drops-out/excluded participants' group (*t*=−1.836, *P*=0.71). There were no significant differences between the observation group and control group with respect to age (independent-samples *t*-test *t*=1.776, *P*=0.082) or disease severity (FEV~1~% predicted) (*t*=0.495, *P*=0.623) ([Table 1](#tbl1){ref-type="table"}).

Correlations between PSQI scores and anxiety, depression and health-related quality of life at baseline
-------------------------------------------------------------------------------------------------------

The correlations between self-reported sleep quality, anxiety, depression and disease-specific health status using data compiled from the 61 patients who entered the study are shown in [Table 2](#tbl2){ref-type="table"}. Poor sleep quality was significantly correlated with high anxiety scores, high depression scores and worse disease-specific health status (*P*⩽0.02). Global PSQI was not associated with disease severity as measured by FEV~1~% predicted (*r*=−0.025, *P*=0.864). Global PSQI score was negatively associated with age (*r*=−0.26, *P*=0.01).

The effect of PR on sleep quality
---------------------------------

There were no significant differences between before and after scores in the observation and control groups with regard to sleep quality (see [Table 3](#tbl3){ref-type="table"}).

When the global PSQI score was broken down into its seven components there were no clinically or statistically significant differences between the pre and post scores in any component.

The effect of PR on depression, anxiety and disease-specific health status
--------------------------------------------------------------------------

The effect of PR on disease-specific health status (CAT), depression and anxiety (HADS) and exercise capacity (ISWT) is shown in [Table 4](#tbl4){ref-type="table"}. There were statistically significant improvements in the observation group pre and post scores with regard to overall disease-specific health status, overall distance walked, and anxiety and depression in those with scores ⩾8 at baseline. The average overall distance walked of 81 m exceeded the MCID of 47.5 m.^[@bib36]^

Discussion
==========

Main findings
-------------

PR had no effect on sleep quality in this controlled study of the effect of PR on sleep in patients with COPD. Most COPD patients undergoing PR had poor sleep quality. The PR treatment was effective in improving quality of life and exercise capacity and in improving depression and anxiety in those with at least mild symptoms, but these effects were not associated with improvements in sleep.

This study was designed to test the concept that PR might improve sleep in participants who received routine referrals to PR. Their characteristics, including the drop-out rate, reflected those of COPD referrals previously reported in this locality and in other studies.^[@bib37],[@bib38]^ The prevalence and severity of poor sleep quality was similar to that already reported in COPD.^[@bib2],[@bib4]^ The extent of improvement in exercise capacity and quality of life, and in mood in those with symptoms of depression or anxiety, showed that the PR treatment was at least as effective as expected. There was no reason to suspect that the lack of effect on sleep quality was due to ineffectiveness of PR.

The strong correlation between sleep quality, health status and depression scores on entry to the study raised the expectation that sleep might improve if quality of life or mood also improved in this group. The absence of improvement in sleep quality even when health status and mood improved was notable. While deterioration in sleep quality in these patients may have occurred in association with or even as a result of deterioration in quality of life and mood, its recovery does not appear to have the same relationship. There was no evidence that poor sleep in COPD was related to exercise capacity.

Strengths and limitations of the study
--------------------------------------

The PSQI is a well-validated, reliable and repeatable tool for the assessment of sleep quality. We acknowledge that polysomnography is the gold standard. In this study we had the additional reassurance of the assessment of sleep quality measured in a control group of comparable COPD patients from the same community. The observation and control groups were not matched, but the quality of sleep of patients in the control group was similar to that in the observation group on entry to the study. We recruited 24 patients into the control group (required sample size 25), but this did not affect the interpretation of the results as there were no differences between the two groups at baseline or in the change in sleep quality over the weeks studied. The control group response rate of 57% was above that observed in other similar COPD studies.^[@bib39],[@bib40]^

Interpretation of findings in relation to previously published work
-------------------------------------------------------------------

The change in PSQI scores we found before and after PR was of a similar magnitude to that recently reported in an observational study by Soler *et al.*^[@bib18]^ Soler *et al.* reported a change in sleep quality following PR in 46 patients with COPD. The authors reported a difference in PSQI scores of 1.1 (6.6--5.5), similar to the reduction of 0.79 (8.04--7.25) in our study. These minimal changes observed are well short of the MCID for the PSQI of 3. We also found a reduction in PSQI scores of a similar magnitude (0.71) in the control group. Soler *et al.* did not recruit a control group.

We were able to demonstrate that PR was effective in our study by reporting an improvement in the walking distance of 81 m, surpassing the MCID for the ISWT of 47.5 m. The PR intervention in the study by Soler *et al.* resulted in an improvement in the 6-min walking distance of approximately 45 m, less than the MCID of 54 m. This suggests that the rehabilitation programme in that study was not achieving the standard improvement in walking distance and brings into question the authors' assertion that changes in sleep quality may have been related to physical activity. Our study shows that despite clinically and statistically significant improvement in walking distance, we observed no concurrent improvement in sleep quality.

With regard to how changes in mood affect sleep, Hynninen *et al.*^[@bib41]^ found that although a course of CBT in COPD patients with known anxiety or depression improved both anxiety and depression, subjective sleep quality as measured by the PSQI did not improve. In our study the close relationship between poor sleep quality and anxiety and depression at baseline was also not reflected in the recovery of sleep with the resolution of anxiety and depression.

Implications for future research, policy and practice
-----------------------------------------------------

The underlying physiological causes of poor sleep in COPD have been well researched, but our understanding of why patients with COPD continue to sleep poorly is limited. A variety of factors are likely to be interacting. Worse quality of life and psychological well-being together with the physiological disruption of daytime and nocturnal hypoxaemia may lead to a disruption in sleep pattern. The chronic insult to sleep architecture, or the onset of a specific symptom that disrupts sleep in an individual, may lead to a change in sleep behaviour that cannot be overcome by simply removing the cause. To address the change in behaviour, which has now become chronic, a systematic approach to poor sleep quality may be required. Cognitive behavioural therapy for insomnia, which includes basic sleep hygiene, has shown promising results in patients with COPD but requires more study.^[@bib42]^

Conclusions
-----------

Poor sleep is a common outcome of COPD, which does not improve with the improvements in quality of life or with the relief of psychological distress that is achieved by participation in PR. It is therefore likely that restoration of the pattern of sleep in COPD will require more specific interventions that aim to restore sleep behaviour without reference to the original cause.
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###### Demographics of observation group patients who completed PR, control group and observation group drop-out/excluded participants

                               *Observation group completed (*n*=28)*   *Control group (*n*=24)*   *Observation group drop-out/excluded (*n*=33)*
  --------------------------- ---------------------------------------- -------------------------- ------------------------------------------------
  Age (years) (s.d.)                        68.1 (11.3)                        73.1 (8.5)                           62.67 (11.1)
  Gender                                   13 (46%) male                     11 (46%) male                         15 (45%) male
  FEV~1~ % predicted (s.d.)            55% (19.2) *(n*=27*)*             57% (15.5) *(n*=23*)*                 49% (16.3) *(n*=30*)*
  FEV~1~/FVC ratio (s.d.)                   0.49 (12.1)                       0.55 (11.7)                           0.53 (12.0)
  Initial PSQI score (s.d.)                  8.04 (4.6)                        9.04 (5.3)                           10.21 (4.6)

Abbreviations: FEV~1~, forced expiratory volume in 1 s; FVC=forced vital capacity; *n*, number in group; PSQI, Pittsburgh Sleep Quality Index; s.d., standard deviation.

###### Correlation between sleep quality, anxiety, depression and health-related quality of life at baseline

  r-*value*                     *PSQI*                                   *CAT*                                  *HADS-A*                                 *HADS-D*                                  *ISWT*
  ------------- --------------------------------------- ---------------------------------------- --------------------------------------- ---------------------------------------- ----------------------------------------
  PSQI (*n*)                    1 (61)                   0.523[a](#t2-fn1){ref-type="fn"} (60)    0.461[a](#t2-fn1){ref-type="fn"} (57)   0.410[a](#t2-fn1){ref-type="fn"} (57)                 −0.161 (48)
  CAT (*n*)      0.523[a](#t2-fn1){ref-type="fn"} (60)                   1 (60)                   0.429[a](#t2-fn1){ref-type="fn"} (57)   0.300[b](#t2-fn2){ref-type="fn"} (57)    −0.401[a](#t2-fn1){ref-type="fn"} (48)
  HAD-A (*n*)    0.461[a](#t2-fn1){ref-type="fn"} (57)   0.429[a](#t2-fn1){ref-type="fn"} (60)                   1 (57)                   0.609[a](#t2-fn1){ref-type="fn"} (57)                 −0.128 (48)
  HAD-D (*n*)    0.410[a](#t2-fn1){ref-type="fn"} (57)   0.300[b](#t2-fn2){ref-type="fn"} (57)    0.609[a](#t2-fn1){ref-type="fn"} (57)                   1 (57)                   −0.346[b](#t2-fn2){ref-type="fn"} (48)
  ISWT (*n*)                  −0.161 (48)                −0.401[a](#t2-fn1){ref-type="fn"} (48)                −0.128 (48)                −0.346[b](#t2-fn2){ref-type="fn"} (48)                   1 (48)

Abbreviations: CAT=COPD assessment test; HADS-A, Hospital Anxiety and Depression Scale---anxiety score; HADS-D, Hospital Anxiety and Depression Scale---depression score; ISWT, incremental shuttle walk test; *n*, number in group; PSQI=Pittsburgh Sleep Quality Index at baseline.

Correlation is significant at the 0.01 level (2-tailed).

Correlation is significant at the 0.05 level (2-tailed).

###### Global PSQI scores for observation and control groups

                                  *Pre*        *Post*       *Difference (95% CI)*   t-*test*   P *value*
  ------------------------------- ------------ ------------ ----------------------- ---------- -----------
  *Observation*                                                                                
   PSQI score (s.d.) *(n*=*28)*   8.04 (4.6)   7.25 (4.7)   0.79 (−0.35 to 1.93)    1.41       0.170
                                                                                               
  *Control*                                                                                    
   PSQI score (s.d.) *(n*=*24)*   9.04 (5.3)   8.33 (4.7)   0.71 (−0.56 to 1.98)    1.15       0.261

Abbreviations: *n*, number in group; PSQI, Pittsburgh Sleep Quality Index; s.d., standard deviation.

###### The effect of PR on disease-specific health status (CAT score), anxiety (HADS), depression (HADS) and exercise capacity (ISWT) (observation group)

                                                 *Pre*            *Post*      *Difference*           *t-test*   P*value*
  ----------------------------------------- ---------------- ---------------- ---------------------- ---------- ----------
  CAT score (s.d.) *(n*=27)                   19.30 (7.6)      16.30 (9.1)    3.00 (0.70--5.30)      2.68       0.013
  HADS---anxiety score (s.d.) *(n*=27)         7.52 (5.1)       6.63 (4.9)    0.89 (−0.36 to 2.14)   1.46       0.16
  Anxiety score⩾8 (s.d.) *(n=12)*             12.25 (3.4)       9.92 (4.8)    2.33 (0.45--4.22)      2.73       0.020
  HADS---depression score (s.d.) *(n*=27)      5.96 (4.8)       4.96 (3.9)    1.00 (−0.16 to 2.16)   1.77       0.09
  Depression score⩾8 (s.d.) *(n=*10)          11.00 (3.8)       8.10 (3.8)    2.90 (1.92--3.88)      6.69       \<0.0001
  ISWT (m) (s.d.) *(n*=20)                   295.50 (126.0)   376.50 (189.6)  81.0 (15.3--146.6)     2.54       0.018

Abbreviations: CAT, COPD assessment test; HADS, Hospital Anxiety and Depression Scale; ISWT, incremental shuttle walk test; PR, pulmonary rehabilitation; s.d., standard deviation.
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